Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Liver Diseases

  Free Subscription


Articles published in Semin Liver Dis

Retrieve available abstracts of 99 articles:
HTML format



Single Articles


    March 2024
  1. KODAMA T, Takehara T
    Molecular genealogy of metabolic-associated hepatocellular carcinoma.
    Semin Liver Dis. 2024 Mar 18. doi: 10.1055/a-2289-2298.
    PubMed     Abstract available


    February 2024
  2. ROMERO-GOMEZ M, Arab JP, Oliveira CP, Hernandez M, et al
    Is There a Safe Alcohol Consumption Limit for the General Population and in Patients with Liver Disease?
    Semin Liver Dis. 2024;44:69-78.
    PubMed     Abstract available


  3. CANIVET CM, Boursier J, Loomba R
    New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice.
    Semin Liver Dis. 2024;44:35-42.
    PubMed     Abstract available


  4. MOUZAKI M, Woo JG, Divanovic S
    Gestational and Developmental Contributors of Pediatric MASLD.
    Semin Liver Dis. 2024;44:43-53.
    PubMed     Abstract available


  5. TUTUSAUS A, Morales A, Garcia de Frutos P, Mari M, et al
    GAS6/TAM Axis as Therapeutic Target in Liver Diseases.
    Semin Liver Dis. 2024;44:99-114.
    PubMed     Abstract available


  6. BESSONE F, Hillotte GL, Ahumada N, Jaureguizahar F, et al
    UDCA for Drug-Induced Liver Disease: Clinical and Pathophysiological Basis.
    Semin Liver Dis. 2024;44:1-22.
    PubMed     Abstract available


  7. EL-KASSAS M, Awad A, Elbadry M, Arab JP, et al
    Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Semin Liver Dis. 2024;44:54-68.
    PubMed     Abstract available


  8. BECH KT, Lindvig KP, Thiele M, Castera L, et al
    Algorithms for Early Detection of Silent Liver Fibrosis in the Primary Care Setting.
    Semin Liver Dis. 2024;44:23-34.
    PubMed     Abstract available


    January 2024
  9. LIU H, Sethi V, Li X, Xiao Y, et al
    Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future.
    Semin Liver Dis. 2024 Jan 11. doi: 10.1055/a-2242-7543.
    PubMed     Abstract available


    November 2023
  10. BALOGUN O, Nejak-Bowen K
    The Hepatic Porphyrias: Revealing the Complexities of a Rare Disease.
    Semin Liver Dis. 2023 Nov 16. doi: 10.1055/s-0043-1776760.
    PubMed     Abstract available


  11. WILSON SR, Duncan AW
    The Ploidy State as a Determinant of Hepatocyte Proliferation.
    Semin Liver Dis. 2023 Nov 15. doi: 10.1055/a-2211-2144.
    PubMed     Abstract available


  12. HAN X, Sun Q, Xu M, Zhu G, et al
    Unraveling the Complexities of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Semin Liver Dis. 2023 Nov 6. doi: 10.1055/s-0043-1776127.
    PubMed     Abstract available


  13. SAEIDINEJAD M, Elshabrawi A, Sriphoosanaphan S, Andreola F, et al
    Novel Therapeutic Approaches in Treatment of Acute-on-Chronic Liver Failure.
    Semin Liver Dis. 2023;43:429-445.
    PubMed     Abstract available


  14. DUTTA RK, Jun J, Du K, Diehl AM, et al
    Hedgehog Signaling: Implications in Liver Pathophysiology.
    Semin Liver Dis. 2023;43:418-428.
    PubMed     Abstract available


    August 2023
  15. PEKARSKA K, Parker R
    Alcohol-Related Liver Disease: Is There a Safe Alcohol Consumption Limit for Liver Disease?
    Semin Liver Dis. 2023;43:305-310.
    PubMed     Abstract available


  16. RANJBARIAN T, Schnabl B
    Gut Microbiome-Centered Therapies for Alcohol-Associated Liver Disease.
    Semin Liver Dis. 2023;43:311-322.
    PubMed     Abstract available


  17. DESHMUKH K, Apte U
    The Role of Endoplasmic Reticulum Stress Response in Liver Regeneration.
    Semin Liver Dis. 2023;43:279-292.
    PubMed     Abstract available


  18. MEADOWS V, Yang Z, Basaly V, Guo GL, et al
    FXR Friend-ChIPs in the Enterohepatic System.
    Semin Liver Dis. 2023;43:267-278.
    PubMed     Abstract available


  19. COOPER SA, Kostallari E, Shah VH
    Angiocrine Signaling in Sinusoidal Health and Disease.
    Semin Liver Dis. 2023;43:245-257.
    PubMed     Abstract available


  20. RUIZ M, Lacaille F, Schrader C, Pons M, et al
    Pediatric and Adult Liver Disease in Alpha-1 Antitrypsin Deficiency.
    Semin Liver Dis. 2023;43:258-266.
    PubMed     Abstract available


    May 2023
  21. KOTULKAR M, Robarts D, Apte U
    HNF4-alpha in hepatocyte health and disease.
    Semin Liver Dis. 2023 May 22. doi: 10.1055/a-2097-0660.
    PubMed     Abstract available


  22. VANDERSCHUEREN E, Trebicka J, Laleman W
    Endoscopic Advances in Hepatology.
    Semin Liver Dis. 2023 May 16. doi: 10.1055/s-0043-1769009.
    PubMed     Abstract available


  23. ADORI M, Bhat S, Gramignoli R, Valladolid-Acebes I, et al
    Hepatic Innervations and Nonalcoholic Fatty Liver Disease.
    Semin Liver Dis. 2023 May 8. doi: 10.1055/s-0043-57237.
    PubMed     Abstract available


  24. GOLABI P, Shah D, Younossi ZM
    How to Identify Advanced Nonalcoholic Fatty Liver Disease in the Primary Care Setting.
    Semin Liver Dis. 2023;43:142-148.
    PubMed     Abstract available


  25. REVERTER E, Toapanta D, Bassegoda O, Zapatero J, et al
    Critical Care Management of Acute-on-Chronic Liver Failure: Certainties and Unknowns.
    Semin Liver Dis. 2023;43:206-217.
    PubMed     Abstract available


  26. GU W, Kimmann M, Laleman W, Praktiknjo M, et al
    To TIPS or Not to TIPS in High Risk of Variceal Rebleeding and Acute-on-Chronic Liver Failure.
    Semin Liver Dis. 2023;43:189-205.
    PubMed     Abstract available


  27. BERNARD JK, Marakovits C, Smith LG, Francis H, et al
    Mast Cell and Innate Immune Cell Communication in Cholestatic Liver Disease.
    Semin Liver Dis. 2023;43:226-233.
    PubMed     Abstract available


  28. SINGH S, Kumar PVSNK, Kumar JP, Tomo S, et al
    Genetic and Epigenetic Basis of Drug-Induced Liver Injury.
    Semin Liver Dis. 2023;43:163-175.
    PubMed     Abstract available


  29. URIAS E, Chen VL
    Screening for At-Risk Nonalcoholic Fatty Liver Disease in the Primary Care Setting.
    Semin Liver Dis. 2023;43:133-141.
    PubMed     Abstract available


    February 2023
  30. KIM M, Rizvi F, Shin D, Gouon-Evans V, et al
    Update on Hepatobiliary Plasticity.
    Semin Liver Dis. 2023 Feb 10. doi: 10.1055/s-0042-1760306.
    PubMed     Abstract available


  31. KELTY TJ, Dashek RJ, Arnold WD, Rector RS, et al
    Emerging Links between Nonalcoholic Fatty Liver Disease and Neurodegeneration.
    Semin Liver Dis. 2023;43:77-88.
    PubMed     Abstract available


  32. OXLEY M, Francis H, Sato K
    Growth Hormone Signaling in Liver Diseases: Therapeutic Potentials and Controversies.
    Semin Liver Dis. 2023;43:24-30.
    PubMed     Abstract available


  33. CHOLANKERIL G, El-Serag HB
    Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
    Semin Liver Dis. 2023;43:89-99.
    PubMed     Abstract available


    January 2023
  34. SMITH TN, Gallo De Moraes A, Simonetto DA
    Cirrhosis management in the Intensive Care Unit.
    Semin Liver Dis. 2023 Jan 18. doi: 10.1055/a-2015-1290.
    PubMed     Abstract available


    December 2022
  35. BANC-HUSU AM, Shiau H, Dike P, Shneider BL, et al
    Beyond Varices: Complications of Cirrhotic Portal Hypertension in Pediatrics.
    Semin Liver Dis. 2022 Dec 26. doi: 10.1055/s-0042-1759613.
    PubMed     Abstract available


  36. LITTLE A, Medford A, O'Brien A, Childs J, et al
    Recent Advances in Intrahepatic Biliary Epithelial Heterogeneity.
    Semin Liver Dis. 2022 Dec 15. doi: 10.1055/s-0042-1758833.
    PubMed     Abstract available


    November 2022
  37. ROMERO-GOMEZ M, Aller R, Martin-Bermudo F
    Dietary Recommendations for the Management of Non-alcoholic Fatty Liver Disease (NAFLD): A Nutritional Geometry Perspective.
    Semin Liver Dis. 2022;42:434-445.
    PubMed     Abstract available


  38. CHEN B, Tang WHW, Rodriguez M, Corey KE, et al
    NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity?
    Semin Liver Dis. 2022;42:465-474.
    PubMed     Abstract available


  39. PARK Y, Thadasina D, Bolujo I, Isidan A, et al
    Three-Dimensional Organoids as a Model to Study Nonalcoholic Fatty Liver Disease.
    Semin Liver Dis. 2022;42:423-433.
    PubMed     Abstract available


  40. MOTOMURA T, Faccioli LAP, Diaz-Aragon R, Kocas-Kilicarslan ZN, et al
    From a Single Cell to a Whole Human Liver: Disease Modeling and Transplantation.
    Semin Liver Dis. 2022;42:413-422.
    PubMed     Abstract available


  41. HUANG DQ, Downes M, Evans RM, Witztum JL, et al
    Shared Mechanisms between Cardiovascular Disease and NAFLD.
    Semin Liver Dis. 2022;42:455-464.
    PubMed     Abstract available


    October 2022
  42. JUANOLA A, Ma AT, Pose E, Gines P, et al
    Novel biomarkers of AKI in cirrhosis.
    Semin Liver Dis. 2022 Oct 3. doi: 10.1055/a-1954-4136.
    PubMed     Abstract available


    September 2022
  43. GALA K, Abdul Razzak F, Rapaka B, Dayyeh Bk A, et al
    Novel Endoscopic Bariatric Therapies for the Management of Non-Alcoholic Steatohepatitis.
    Semin Liver Dis. 2022 Sep 18. doi: 10.1055/a-1946-6285.
    PubMed     Abstract available


  44. GOFTON C, Agar M, George J
    Early Implementation of Palliative and Supportive Care in Hepatocellular Carcinoma.
    Semin Liver Dis. 2022 Sep 17. doi: 10.1055/a-1946-5592.
    PubMed     Abstract available


  45. RASHA F, Paul S, Simon TG, Hoshida Y, et al
    Hepatocellular carcinoma chemoprevention with generic agents.
    Semin Liver Dis. 2022 Sep 14. doi: 10.1055/a-1942-6693.
    PubMed     Abstract available


    August 2022
  46. TUJIOS S, Stravitz RT, Lee WM
    Management of Acute Liver Failure: Update 2022.
    Semin Liver Dis. 2022;42:362-378.
    PubMed     Abstract available


  47. CARVALHO-GONTIJO R, Han C, Zhang L, Zhang V, et al
    Metabolic Injury of Hepatocytes Promotes Progression of NAFLD and AALD.
    Semin Liver Dis. 2022;42:233-249.
    PubMed     Abstract available


  48. CASTERA L, Boursier J
    Noninvasive Algorithms for the Case Finding of "At-Risk" Patients with NAFLD.
    Semin Liver Dis. 2022;42:313-326.
    PubMed     Abstract available


  49. EL-KASSAS M, Cabezas J, Coz PI, Zheng MH, et al
    Nonalcoholic Fatty Liver Disease: Current Global Burden.
    Semin Liver Dis. 2022;42:401-412.
    PubMed     Abstract available


  50. ATIF J, Thoeni C, Bader GD, McGilvray ID, et al
    Unraveling the Complexity of Liver Disease One Cell at a Time.
    Semin Liver Dis. 2022;42:250-270.
    PubMed     Abstract available


  51. NEVENS F, van der Merwe S
    Mesenchymal Stem Cell Transplantation in Liver Diseases.
    Semin Liver Dis. 2022;42:283-292.
    PubMed     Abstract available


    June 2022
  52. GARCIA-SAENZ-DE-SICILIA M, Al-Obaid L, Hughes DL, Duarte-Rojo A, et al
    Mastering core recommendations during HEPAtology ROUNDS in advanced chronic liver disease.
    Semin Liver Dis. 2022 Jun 28. doi: 10.1055/a-1886-5909.
    PubMed     Abstract available


  53. CHEW N, Ng CH, Truong E, Noureddin M, et al
    Non-Alcoholic Steatohepatitis Drug Development Pipeline: An Update.
    Semin Liver Dis. 2022 Jun 16. doi: 10.1055/a-1877-9656.
    PubMed     Abstract available


  54. KULKARNI AV, Premkumar M, Arab JP, Kumar K, et al
    EARLY DIAGNOSIS AND PREVENTION OF INFECTIONS IN CIRRHOSIS.
    Semin Liver Dis. 2022 Jun 7. doi: 10.1055/a-1869-7607.
    PubMed     Abstract available


    May 2022
  55. GRINSPAN LT, Villanueva A
    Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma.
    Semin Liver Dis. 2022;42:188-201.
    PubMed     Abstract available


  56. YUAN WZ, Fu T
    Liver Dysfunction in COVID-19: From Onset to Recovery.
    Semin Liver Dis. 2022;42:151-158.
    PubMed     Abstract available


  57. GUPTA B, Rai R, Oertel M, Raeman R, et al
    Intestinal Barrier Dysfunction in Fatty Liver Disease: Roles of Microbiota, Mucosal Immune System, and Bile Acids.
    Semin Liver Dis. 2022;42:122-137.
    PubMed     Abstract available


  58. TARLI C, Mirijello A, Addolorato G
    Treating Alcohol Use Disorder in Patients with Alcohol-Associated Liver Disease: Controversies in Pharmacological Therapy.
    Semin Liver Dis. 2022;42:138-150.
    PubMed     Abstract available


  59. FASULLO M, Shah T, Zhou H, Siddiqui MS, et al
    Post-Transplant Biliary Strictures: An Updated Review.
    Semin Liver Dis. 2022;42:225-232.
    PubMed     Abstract available


  60. CARROLL HK, Duffy AG, O'Farrelly C
    Liver Immunology, Immunotherapy, and Liver Cancers: Time for a Rethink?
    Semin Liver Dis. 2022;42:212-224.
    PubMed     Abstract available


    February 2022
  61. GALLAHER CE, Shawcross DL
    Management of multidrug-resistant infections in cirrhosis.
    Semin Liver Dis. 2022 Feb 7. doi: 10.1055/a-1765-0056.
    PubMed     Abstract available


  62. PANDAY R, Monckton CP, Khetani SR
    The Role of Liver Zonation in Physiology, Regeneration, and Disease.
    Semin Liver Dis. 2022;42:1-16.
    PubMed     Abstract available


  63. CADAMURO M, Lasagni A, Sarcognato S, Guido M, et al
    The Neglected Role of Bile Duct Epithelial Cells in NASH.
    Semin Liver Dis. 2022;42:34-47.
    PubMed     Abstract available


  64. TERZI E, Ayuso C, Piscaglia F, Bruix J, et al
    Liver Imaging Reporting and Data System: Review of Pros and Cons.
    Semin Liver Dis. 2022;42:104-111.
    PubMed     Abstract available


    November 2021
  65. TELLEZ L, Rodriguez de Santiago E, Albillos A
    Fontan-Associated Liver Disease: Pathophysiology, Staging, and Management.
    Semin Liver Dis. 2021;41:538-550.
    PubMed     Abstract available


  66. RADUN R, Trauner M
    Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities.
    Semin Liver Dis. 2021;41:461-475.
    PubMed     Abstract available


  67. MAIWALL R, Sarin SK
    Plasma Exchange in Acute and Acute on Chronic Liver Failure.
    Semin Liver Dis. 2021;41:476-494.
    PubMed     Abstract available


  68. GU X, Lu Q, Zhang C, Tang Z, et al
    Clinical Application and Progress of Fecal Microbiota Transplantation in Liver Diseases: A Review.
    Semin Liver Dis. 2021;41:495-506.
    PubMed     Abstract available


  69. MENDOZA YP, Becchetti C, Watt KD, Berzigotti A, et al
    Risks and Rewards of Bariatric Surgery in Advanced Chronic Liver Diseases.
    Semin Liver Dis. 2021;41:448-460.
    PubMed     Abstract available


  70. HASHEM A, Khalouf A, Acosta A
    Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review.
    Semin Liver Dis. 2021;41:435-447.
    PubMed     Abstract available


  71. ARRESE M, Arab JP, Barrera F, Kaufmann B, et al
    Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity.
    Semin Liver Dis. 2021;41:421-434.
    PubMed     Abstract available


  72. KOHUT TJ, Gilbert MA, Loomes KM
    Alagille Syndrome: A Focused Review on Clinical Features, Genetics, and Treatment.
    Semin Liver Dis. 2021;41:525-537.
    PubMed     Abstract available


  73. LI N, Yamamoto G, Fuji H, Kisseleva T, et al
    Interleukin-17 in Liver Disease Pathogenesis.
    Semin Liver Dis. 2021;41:507-515.
    PubMed     Abstract available


    October 2021
  74. JENG WJ, Liaw YF
    Erratum to: Finite Antiviral Therapy in Chronic Hepatitis B Patients with Cirrhosis.
    Semin Liver Dis. 2021 Oct 1. doi: 10.1055/s-0041-1737024.
    PubMed    


    September 2021
  75. MARIN JJG, Romero MR, Herraez E, Asensio M, et al
    Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems.
    Semin Liver Dis. 2021 Sep 20. doi: 10.1055/s-0041-1735631.
    PubMed     Abstract available


    August 2021
  76. SHERMAN M
    Assessing Toxicity in Drug Trials in Liver Disease.
    Semin Liver Dis. 2021;41:277-284.
    PubMed     Abstract available


  77. KAWAGUCHI T, Charlton M, Kawaguchi A, Yamamura S, et al
    Effects of Mediterranean Diet in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials.
    Semin Liver Dis. 2021;41:225-234.
    PubMed     Abstract available


  78. ZELBER-SAGI S
    Dietary Treatment for NAFLD: New Clinical and Epidemiological Evidence and Updated Recommendations.
    Semin Liver Dis. 2021;41:248-262.
    PubMed     Abstract available


  79. NILLES KM, Levitsky J
    Current and Evolving Indications for Simultaneous Liver Kidney Transplantation.
    Semin Liver Dis. 2021;41:308-320.
    PubMed     Abstract available


  80. MA L, Khatib S, Craig AJ, Wang XW, et al
    Toward a Liver Cell Atlas: Understanding Liver Biology in Health and Disease at Single-Cell Resolution.
    Semin Liver Dis. 2021;41:321-330.
    PubMed     Abstract available


  81. MOLLER S, Kimer N, Kronborg T, Grandt J, et al
    Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms.
    Semin Liver Dis. 2021;41:235-247.
    PubMed     Abstract available


  82. ENGELMANN C, Martino VD, Kerbert AJC, Weil-Verhoeven D, et al
    The Current Status of Granulocyte-Colony Stimulating Factor to Treat Acute-on-Chronic Liver Failure.
    Semin Liver Dis. 2021;41:298-307.
    PubMed     Abstract available


    July 2021
  83. VAZ K, Goodwin T, Kemp W, Roberts S, et al
    Artificial Intelligence in Hepatology: A Narrative Review.
    Semin Liver Dis. 2021 Jul 29. doi: 10.1055/s-0041-1731706.
    PubMed     Abstract available


  84. ZHOU Y, Tao J, Calvisi DF, Chen X, et al
    Role of Lipogenesis Rewiring in Hepatocellular Carcinoma.
    Semin Liver Dis. 2021 Jul 26. doi: 10.1055/s-0041-1731709.
    PubMed     Abstract available


  85. KAHL S, Putzer J, Roden M
    Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis.
    Semin Liver Dis. 2021 Jul 21. doi: 10.1055/s-0041-1732354.
    PubMed     Abstract available


    June 2021
  86. JENG WJ, Liaw YF
    Finite Antiviral Therapy in Chronic Hepatitis B Patients with Cirrhosis.
    Semin Liver Dis. 2021 Jun 28. doi: 10.1055/s-0041-1729973.
    PubMed     Abstract available


  87. HSU YC, Tseng CH, Huang YT, Yang HI, et al
    Application of Risk Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: Current Status and Future Perspective.
    Semin Liver Dis. 2021 Jun 23. doi: 10.1055/s-0041-1730924.
    PubMed     Abstract available


  88. BRESSON-HADNI S, Spahr L, Chappuis F
    Hepatic Alveolar Echinococcosis.
    Semin Liver Dis. 2021 Jun 23. doi: 10.1055/s-0041-1730925.
    PubMed     Abstract available


  89. SU YY, Li CC, Lin YJ, Hsu C, et al
    Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives.
    Semin Liver Dis. 2021 Jun 15. doi: 10.1055/s-0041-1730949.
    PubMed     Abstract available


    May 2021
  90. HAEP N, Florentino RM, Squires JE, Bell A, et al
    The Inside-Out of End-Stage Liver Disease: Hepatocytes are the Keystone.
    Semin Liver Dis. 2021 May 15. doi: 10.1055/s-0041-1725023.
    PubMed     Abstract available


  91. USON JUNIOR PLS, Nagalo BM, Ahn DH, Bekaii-Saab T, et al
    Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?
    Semin Liver Dis. 2021 May 6. doi: 10.1055/s-0040-1722646.
    PubMed     Abstract available


  92. MOECKLI B, Majno P, Orci LA, Peloso A, et al
    Liver Transplantation Selection and Allocation Criteria for Hepatocellular Carcinoma: A European Perspective.
    Semin Liver Dis. 2021 May 6. doi: 10.1055/s-0041-1723032.
    PubMed     Abstract available


  93. SEKIBA K, Otsuka M, Koike K
    Potential of HBx Gene for Hepatocarcinogenesis in Noncirrhotic Liver.
    Semin Liver Dis. 2021 May 6. doi: 10.1055/s-0041-1723033.
    PubMed     Abstract available


  94. GIL-GOMEZ A, Brescia P, Rescigno M, Romero-Gomez M, et al
    Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers.
    Semin Liver Dis. 2021;41:191-205.
    PubMed     Abstract available


  95. ORTIZ V, Ellenberg SS, Weinberg EM
    Blinding in Clinical Trials for Chronic Liver Diseases.
    Semin Liver Dis. 2021;41:163-171.
    PubMed     Abstract available


  96. DUNN MA, Kappus MR, Bloomer PM, Duarte-Rojo A, et al
    Wearables, Physical Activity, and Exercise Testing in Liver Disease.
    Semin Liver Dis. 2021;41:128-135.
    PubMed     Abstract available


    January 2021
  97. HARTMANN P, Schnabl B
    New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease.
    Semin Liver Dis. 2021;41:87-102.
    PubMed     Abstract available


  98. FERREIRA-GONZALEZ S, Rodrigo-Torres D, Gadd VL, Forbes SJ, et al
    Cellular Senescence in Liver Disease and Regeneration.
    Semin Liver Dis. 2021;41:50-66.
    PubMed     Abstract available


  99. WANG H, Calvisi DF, Chen X
    Organoids for the Study of Liver Cancer.
    Semin Liver Dis. 2021;41:19-27.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.